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Neurological Implications of
Transcatheter Aortic Valve Replacement*Vinod H. Thourani, MD, Lillian Tsai, AB, Hanna Jensen, MD, PHDI n this issue of the Journal, Bosmans et al. (1)report much-awaited stroke outcomes fromthe ADVANCE study, a multicenter, prospective,
nonrandomized cohort of patients undergoing trans-
catheter aortic valve replacement (TAVR) with the
CoreValve prosthesis (Medtronic Inc., Minneapolis,
Minnesota) at 44 mostly European sites between
March 2010 and July 2011. In this real-world cohortSEE PAGE 209of patients with severe aortic stenosis, the investiga-
tors observed stroke rates of 3.0% at 30 days post-
TAVR and 5.6% at 2 years. They reported no signiﬁcant
predictors of periprocedural stroke or transient
ischemic attack (TIA) occurring within the ﬁrst post-
operative day but demonstrated an association be-
tween acute kidney injury, female sex, or major
vascular complication and 30-day stroke. The only
predictor of long-term stroke was a prior coronary ar-
tery bypass grafting operation.
These data come at an intriguing time. The ﬁeld is
currently seeing reports from randomized controlled
trials in which a survival beneﬁt and a reduction
in the rate of major adverse cardiovascular and cere-
brovascular events in TAVR patients is suggested,
for the ﬁrst time, compared with surgical aortic*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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balloon-expandable valve systems are evolving to
an extent at which the rate of moderate or greater
paravalvular leak is almost insigniﬁcant (3–5). Clinical
trials are recruiting intermediate-risk patients to un-
dergo a treatment that only 5 short years ago was
reserved for those with no other options. Rare in-
novations in cardiac surgery have had the momentum
of TAVR, equally complemented and driven by the
constant, ﬂuid evolution of valve systems and de-
livery devices. Robust, structured, and monitored
research must sprint to keep up.
When the results of the randomized controlled
landmark PARTNER (Placement of Aortic Trans-
catheter Valves) trial that led to U.S. Food and Drug
Administration approval of the balloon-expandable
valve were published, there was cause for alarm in
terms of neurological outcomes: An increased risk
of operative stroke and TIA was observed in
TAVR patients compared with SAVR patients (6,7).
Although cardiopulmonary bypass and aortic cross-
clamping, the traditional nemeses of cerebral circu-
lation, were avoided in this novel transcatheter
intervention, 30-day stroke rates were quoted to be
as high as 5.0% for inoperable patients and 3.8%
for patients with high surgical risk (6,7). Subsequent
studies speculated that temporary circulatory dis-
ruptions during balloon valvuloplasty or rapid
ventricular pacing may have led to periods of sub-
optimal cerebral perfusion and ischemia (8), or
that valvular calcium deposits, tissue factor, and
thrombin reserves from the diseased native valve
were released into the circulation, triggering co-
agulation cascades that led to increased throm-
bogenicity (9). It is very likely that the larger
ﬁrst-generation devices that crossed the aortic arch
also played a signiﬁcant role in the seemingly high
stroke rate with TAVR.
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219However, more contemporary comparisons have
largely mitigated the difference in stroke risk in TAVR
compared with SAVR. In a recent study that specif-
ically examined neurological outcomes in patients
with aortic stenosis, there were no differences in
overall neurological injury, cerebral embolic load,
ischemic lesions, or oxygen desaturation in patients
undergoing SAVR or TAVR (10). It is likely that the
technology development that has led to smaller de-
vices manipulated in the arch has neutralized, at least
in part, the risk proﬁle between the interventions.
The Society of Thoracic Surgeons (STS) and American
College of Cardiology Transcatheter Valve Therapies
registry, which documents the commercial TAVR
experience in the U.S. post–Food and Drug Adminis-
tration approval, quoted a stroke rate as low as 2.0%
at 30 days (11) and 4.1% at 1 year after TAVR (12), with
these data gathered approximately 1 year after the
recruitment of the ADVANCE study patients.
Although it fortunately appears that stroke rates in
TAVR are diminishing, it is undeniable that perma-
nent neurological injury is the single most signiﬁcant
and most feared morbidity of cardiac interventions.
A debilitating stroke is viewed by many as the greater
evil, even compared with operative death. As the
target audience for TAVR expands, the identiﬁcation
of any procedural risk factors for neurological com-
plications is imperative, an effort to which the current
paper by Bosmans et al. (1) commendably contributes.
Nevertheless, a few words of caution, recognized by
the authors but further emphasized in this editorial,
are in order.
The patients in the ADVANCE study were healthier
(mean STS score <9%) than patients enrolled in pre-
vious randomized controlled trials. This, combined
with the fact that TAVR procedures were undertaken
in experienced centers, led to a fairly low stroke rate,
which although fortunate clinically, limits the rele-
vance of especially the multivariable analysis in the
presence of very few events. The interpretation of
these data must be done while the possibility of type
II error is kept in mind; although a large cohort was
enrolled, the study may be a victim of the in-
vestigators’ success in avoiding neurological compli-
cations, and thus, some important risk factors may
have been masked.
Second, neurological events were not actively
sought; they were reported when identiﬁed. A
concern from the clinical team led to a review by an
on-site neurologist, followed by an independent
neurologist, and ﬁnally, the event was retrospectively
adjudicated by the clinical events committee of the
study using Valve Academic Research Consortium
criteria. Thus, although there is little doubt that thereported events were thoroughly investigated and
appropriately reported, in the absence of rigorous
neurological review before and after the procedure,
the possibility of neurological events having gone
undetected exists.
Indeed, in a previous prospective 200-patient
cohort undergoing SAVR, when patients underwent
thorough review by neurologists preoperatively and
on postoperative days 1, 3, and 7 accompanied by
routine postoperative cerebral magnetic resonance
imaging, the clinical stroke rate was a whopping
17%, much higher than in any previously reported
contemporary studies (13). At the same time, the re-
ported stroke rate in the STS database for this same
patient population was only 7%, which highlights the
difference between stroke that is reported rather than
stroke that is actively sought. Furthermore, in this
same patient cohort, subclinical infarct on neuro-
imaging was detected in more than one-half of the
patients, an important reminder that there is no room
for complacency in the quest for effective neuro-
protection in cardiac interventions. Although the
level of neurological surveillance described in the
study by Messé et al. (13) would be challenging for
large national registries such as the STS or the
Transcatheter Valve Therapies registry, any future
prospective study that aims to assess neurological
outcomes and risk factors should follow this rigorous
example as a matter of course.
The risk factors the ADVANCE study identiﬁed for
30-day stroke were female sex, acute kidney injury,
and major vascular complications. As the authors
have speculated, perhaps female patients with
smaller vessels were predisposed to vascular com-
plications, which in turn led to hypotensive episodes
and more maneuvering within the atherosclerotic
vessels. Renal failure may have been a surrogate
marker for a sicker subset of patients, or an under-
lying kidney-brain interaction may have contributed
to the pathophysiology of stroke, as suggested by
some previous data (14). The relationship between
prior coronary artery bypass grafting and late stroke
was likely characterized by more extensive athero-
sclerotic disease. Patients with atrial ﬁbrillation were
at higher risk of a neurological event if stroke and TIA
were combined as an outcome. Because patients
in this study, as routinely in all TAVR programs,
received anticoagulation therapy with a double
regimen of aspirin and clopidogrel for 6 months post-
TAVR, the question of whether hypotensive episodes
played a role in the relationship between AF and
neurological events should be considered.
In the quickly developing arena of TAVR, we
must also remember that even a year can make a
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220difference, because not only do devices and tech-
nology evolve, patient selection by TAVR centers
becomes more reﬁned, and alternative TAVR access
routes are identiﬁed and used with increasing safety
and feasibility (15). It will also be extremely inter-
esting to learn how embolic protection devices in-
ﬂuence neurological outcomes. Pre-clinical and early
clinical data have shown considerable promise for
these devices, which aim to reduce the cerebral
burden of embolic debris by either capturing or
deﬂecting embolized material from supra-aortic
cerebral trunks. With 3 different embolic protection
devices already in the clinical phase, we should
expect results from larger trials soon (16).
In conclusion, the results from the ADVANCE
trial are encouraging. Stroke rates were low, and
no particular procedure-related factors appeared
to predispose patients to neurological events
within the perioperative period. It was clear that theheaviest 30-day stroke burden stemmed from
patient-speciﬁc factors that have been highlighted
by previous studies and are on the clinical radar
when a patient’s eligibility for aortic valve in-
terventions is being assessed. However, neurological
challenges still form a signiﬁcant portion of mor-
bidity and mortality after TAVR and SAVR, and their
more subtle forms will go undetected if not specif-
ically sought. Future studies, like the evolution of
TAVR itself, must maintain a continuous, stringent
drive to identify, prevent, and treat neurological
dysfunction in this susceptible and often vulnerable
patient population.
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